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Abstract
Metformin is an antidiabetic drug. However, the pleiotropic beneficial effects of metformin in 
nondiabetic models still need to be defined. The objective of this study is to investigate the effect 
of metformin on angiotensin II (Ang II)-induced hypertension and cardiovascular diseases. Mice 
were infused with Ang II (400 ng/kg per min) with or without metformin for 2 weeks. Mice 
infused with angiotensin II displayed an increase in blood pressure associated with enhanced 
vascular endoplasmic reticulum (ER) stress markers, which were blunted after metformin 
treatment. Moreover, hypertension-induced reduction in phosphorylated AMPK, endothelial nitric 
oxide synthase (eNOs) phosphorylation, and endothelium-dependent relaxation (EDR) in 
mesenteric resistance arteries (MRA) were rescued after metformin treatment. Infusion of ER 
stress inducer (tunicamycin, Tun) in control mice induced ER stress in MRA and reduced 
phosphorylation of AMPK, eNOS synthase phosphorylation, and EDR in MRA without affecting 
systolic blood pressure (SBP). All these factors were reversed subsequently with metformin 
treatment. ER stress inhibition by metformin improves vascular function in hypertension. 
Therefore, metformin could be a potential therapy for cardiovascular diseases in hypertension 
independent of its effects on diabetes.
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Introduction
Metformin, an oral antidiabetic agent, is usually prescribed as a first-line drug to patients 
with type-2 diabetes mellitus (T2DM) by international guidelines [1]. Clinical studies on the 
effects of metformin on blood pressure (BP) have shown various findings from decreased to 
unaltered BP [2, 3]. Metformin has also been reported to lower BP in spontaneously 
hypertensive rats (SHR) [4]. The protective effect on BP in nondiabetic hypertensives is 
unclear. Thus, the molecular mechanisms that determine the effect of metformin on blood 
vessel responsiveness in relation to lowering blood pressure remain uncharacterized.
The renin–angiotensin–aldosterone system (RAAS) has a central role in vascular adaptive 
processes [5]. The stimulation of this system has been demonstrated in a range of 
cardiovascular disorders, especially in hypertension and hypertension with diabetes mellitus 
[6]. Angiotensin II (Ang II) is a potent vasoconstrictor that plays a key role in BP regulation 
[7]. Furthermore, Ang II is an important component of the RAAS system that alternatively 
controls BP [8]. ER stress has been involved in vascular endothelial dysfunction and cardiac 
damage in an Ang II-induced hypertension model [9]. However, several studies have 
suggested the importance of other mechanisms through which Ang II may regulate the 
progression of hypertension [10].
AMP-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine 
protein kinase that consists of α, β, and γ subunits. AMPK is reported to exert a direct 
vasorelaxant effect in isolated aortic rings [11]. Some studies have demonstrated that AMPK 
is essential in maintaining ER function in vascular smooth muscle cells (VSMCs), and that 
aberrant ER stress might play a causative role in the development and progression of 
hypertension [12]. In endothelial cells (ECs), AMPKα2 deficiency causes aberrant ER stress 
resulting in vascular dysfunction and atherosclerosis in vivo [13]. Published data indicate 
that metformin is a potent activator of AMPK [14]. The aim of the present study is to 
determine whether AMPK-suppressed ER stress by metformin is required to preserve 
endothelial function in an Ang II-induced hypertension model.
Materials and methods
General protocol in mice
All experiments were performed according to the guidelines of Animal Care Committee of 
Shanghai Jiao Tong University School of Medicine. Fifty mice (C57BL/6J, 8-week-old 
males) were purchased from the Shanghai Laboratory Animal Company (Shanghai, China), 
housed in groups of five mice, and maintained at a temperature of 23 °C with a 12 h light/
dark cycle. Mice were fed on a solid standard diet (Na+ content 0.4 %) and water. Mice were 
divided in four groups: (1) sham mice (control mice infused with saline, n = 5), (2) sham 
mice treated with metformin (300 mg.kg−1 body weight per day) in drinking water for 2 
weeks, n = 5, (3) control mice infused with Ang II (400 ng/kg/min) using subcutaneous 
mini-osmotic pumps for 2 weeks (HT, n = 5), and (4) control mice infused with Ang II and 
metformin (300 mg.kg−1 body weight per day) in drinking water for 2 weeks, n = 5. Body 
weight was recorded weekly during the experimental period. The dose of Ang II was 
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selected based on our previous studies [15, 16], and the dose of metformin used was based 
on the literature [17].
Systolic blood pressure (SBP) was measured using the CODA tail-cuff blood pressure 
system (Kent Scientific Torrington, USA). Arterial blood pressure measurements were 
performed at the same time of day (between 9 and 11 a.m.) to avoid the influence of the 
circadian cycle. SBP was obtained by calculating the average of 10 measurements.
At the end of the treatment period, mice were anesthetized with isoflurane. Mesenteric 
resistance arteries (MRA) were then harvested immediately and placed in PSS solution 
(composition in mM: NaCl 118; KCl 4.7; CaCl2 2.5; KH2PO4 1.2; MgSO4×7H2O 1.2; 
NaHCO3 25 and glucose 11, pH = 7.4) to be processed appropriately for further studies.
In another set of experiments, we used 8-week-old C57BL/6J male mice divided into four 
groups: (1) sham group (control received saline, n = 5), (2) sham mice treated with 
metformin (300mg.kg−1 body weight per day) in drinking water for 2 weeks, n = 5, (3) 
control group that received intraperitoneal injection of tunicamycin (Tun, 1 mg/kg, two 
injections/week for 2 weeks, Sham + Tun, n = 5), and (4) control group that received 
tunicamycin and metformin (300 mg.kg−1 body weight per day) in drinking water for 2 
weeks, n = 5. Systolic blood pressure was measured weekly during the treatment period. At 
the end of treatment, mice were anesthetized with isoflurane, and then mesenteric resistance 
arteries were immediately harvested and placed in PSS solution for reactivity and 
biochemistry assays.
Vascular reactivity
MRA from all groups of mice were carefully cleaned by removing adipose and connective 
tissue and were further cut into rings (2 mm in length). MRA were mounted in a small 
vessel dual-chamber myograph for measurement of isometric tension. After a 30-min 
equilibration period in PSS solution bubbled with carbogen at 37 °C and pH = 7.4, arteries 
were stretched to their optimal lumen diameter for active tension development. After a 
second 30-min equilibration period, arteries were stimulated with phenylephrine (PE, 
10−5M) followed by acetylcholine (ACh, 10−6M) to assess the function of endothelial cells. 
After a 1-h incubation, cumulative concentration responses to phenylephrine (PE, 3.10−8 – 
10−4M) and thromboxane analog (U46619,10−9–10−5M) were obtained. In another series of 
experiments, rings were preconstricted with PE (10−4mol/L) and steady maximal 
contraction. Cumulative concentration-response curves were obtained for ACh (1 × 10−8–3 
× 10−5mol/L) and sodium nitroprosside SNP (1 × 10−8 –3 × 10−5mol/L).
Western blot analysis
Western blot analysis for total and phospho eNOS, phospho PERK, total and phospho eIF2-
α, CHOP, GRP78, ATF6, and total and phospho AMPKα (1:1000 dilution, Cell Signaling 
Technology, Inc, USA) was performed in lysates of mesenteric arteries as previously 
described.
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Immunofluorescence
MRA segments were frozen in Tissue Tek OCT embedding medium (Sakura Finetek 
Europe, The Netherlands). Transverse sections were cut 5-μm thick. After blockade in PBS 
containing 5% fetal bovine serum and 0.3% Triton X-100, sections were incubated with 
primary antibodies against 8-hydroxydeoxyguanosine (8-OHDG) (Abcam, Cambridge, 
MA), and von Willebrand factor antibody (Abcam, Cambridge, MA) used at a 1:50–1:200 
dilution followed by a biotinylated secondary antibody for immunofluorescence. 
Immunofluorescent signals were viewed using an Eclipse 55i fluorescence microscope 
(x20), Nikon.
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity assay
Superoxide anion levels generated by NADPH oxidase activity were measured in lysates of 
aorta and MRA using lucigenin chemiluminescence. Briefly, lysates were prepared in a 
sucrose buffer containing 50 mM KH2PO4, 1 mM EGTA, and 150 mM sucrose at a pH of 
7.0 and the “Complete-C mini” protease inhibitor cocktail (Roche Diagnostics, IN) in a 
Tissue Dounce homogenizer on ice, and aliquots of the homogenates were immediately 
used. To start the assay, a volume of 100 μL of each lysate was used in a total volume of 1 
mL of PBS buffer preheated at 37 °C that contained lucigenin (5 μM) and NADPH (100 μM). 
Blank samples were prepared using 100 μL of sucrose buffer. Lucigenin activity was 
measured every 30 s for 10 min in a luminometer (Turner biosystem 20/20, single tube 
luminometer) or until enzymatic activity reached a plateau. Data are expressed as % of the 
area under the curve of relative light units (RLU) normalized to protein content (μg protein) 
compared to sham.
Drugs
Phenylephrine hydrochloride, acetylcholine, NADPH, angiotensin II, and metformin were 
obtained from Sigma–Aldrich (USA). U46619 and tunicamycin were obtained from Tocris 
Bioscience. Stock solutions of drugs were prepared in ultrapure water and stored at −20 °C, 
and appropriate dilutions were made on the day of the experiment.
Statistical analysis
Data are expressed as the mean ± SEM. Concentration-response curves were analyzed using 
GraphPad Prism 4.0 software (GraphPad, USA) and adjusted to a logistic equation. 
Statistical calculations for significant differences were performed using one-way Student’s t-
tests followed by post-hoc tests or two-way ANOVAs as appropriate. Comparisons are 
considered significant when p < 0.05.
Results
Metformin ameliorated angiotensin II-induced systolic blood pressure
We aimed to study the effect of metformin on SBP. Our data demonstrated that mice infused 
with Ang II for 2 weeks had significantly increased SBP compared to the sham group 
infused with saline (Fig. 1a). Interestingly, metformin treatment significantly reduced SBP in 
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Ang II-infused mice (Fig. 1a). Body weight was not affected by treatment and was similar 
among groups (Fig. 1b).
Metformin improved vascular function
To study the effects of metformin treatment on MRA reactivity, we subjected vessels to 
cumulative doses of thromboxane analogue (U46619) and PE. Our data indicate that there 
were no differences in the contractile response between the sham group and the groups 
infused with Ang II in the presence or absence of metformin (Fig. 1c, d). To determine the 
role of metformin in vascular endothelial dysfunction in hypertension, we examined EDR by 
using acetylcholine (Ach). Ang II-induced hypertension attenuated EDR in MRA compared 
with the sham group (Fig. 1e). Interestingly, metformin treatment significantly improved 
EDR (Fig. 1e). Endothelium-independent relaxation to SNP was similar among groups (Fig. 
1f).
Since ACh produces NO through activation of eNOS, we analyzed the protein levels of total 
and phosphorylated eNOS. Our data indicate that Ang II-induced hypertension reduced 
eNOS phosphorylation in MRA, which was restored after metformin treatment (Fig. 1g). 
The expression of total eNOS protein level was similar among all groups of mice (Fig. 1g).
Metformin inhibited ER stress and restored p-AMPK expression
The aim of this experiment was to study the effect of metformin on AMPK kinase. Our data 
indicate that ER stress marker (BIP, p-eIF2α/T-eIF2α, p-PERK, CHOP, and ATF6) 
expression levels in MRA were significantly higher in the Ang II group compared to the 
sham group (Fig. 2a). Metformin treatment significantly reduced ER stress marker 
expression levels (Fig. 2a).
T-AMPK expression in MRA was similar among groups (Fig. 2b). However, the expression 
of p-AMPK was significantly reduced after exposure to Ang II compared to the sham group. 
p-AMPK expression was restored by treatment with metformin (Fig. 2b).
Metformin reduced NADPH activity
This experiment was performed to assess the effect of metformin on oxidative stress. Our 
results showed that NADPH oxidase activity was higher in the Ang II group compared to the 
sham group (Fig. 3a). Interestingly, metformin significantly reduced NADPH oxidase 
activity (Fig. 3a). To confirm our data, we proceeded with an immunostaining experiment 
using von Willebrand factor (vWF) as a marker for blood vessel endothelial cells and 8-
OHDG as a marker for oxidative stress. Our data showed that 8-OHDG was significantly 
increased in the Ang II-infused mice compared to sham mice. Treatment with metformin 
significantly reduced expression of 8-OHDG (Fig. 3b).
Metformin protects against tunicamycin-induced vascular dysfunction
To further determine the relationship between metformin, ER stress, AMPK, and vascular 
dysfunction independent of hypertension, we performed in vivo studies by treating mice 
with an ER stress inducer (tunicamycin) for 2 weeks. The results showed that treatment with 
tunicamycin had no effect on systolic blood pressure (Fig. 4a).
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We did not detect any differences in contractile response to U46619 or PE among groups 
(Fig. 4b, c). EDR that was damaged after tunicamycin treatment was significantly improved 
with metformin treatment (Fig. 4d). Endothelium-independent relaxation to SNP was similar 
among groups (Fig. 4e). We then detected the expression of eNOS, and there was no 
difference in the expression of T-eNOS among groups (Fig. 4f). Phosphorylated eNOS was 
reduced in the tunicamycin mice compared to the sham mice. Interestingly, treatment with 
metformin completely restored the expression of p-eNOS (Fig. 4f).
Metformin inhibited tunicamycin-induced ER stress and restored p-AMPK expression
The rationale of this experiment is to see the effect of metformin on vasculature independent 
of hypertension. Our data showed that ER stress marker (BIP, p-PERK, and CHOP) 
expression levels in MRA were higher in the tunicamycin group compared to the sham 
group (Fig. 5a). Treatment with metformin significantly reduced ER stress marker 
expression levels (Fig. 5a).
T-AMPK expression in MRA was similar among groups (Fig. 5b). The expression of p-
AMPK was largely inhibited by tunicamycin but was restored with metformin (Fig. 5b).
Metformin reduced NADPH activity induced by tunicamycin
This experiment was performed to elucidate the role of metformin in NADPH oxidase 
activity independent of increased SBP. Our data demonstrated that NADPH oxidase activity 
was significantly increased in mice treated with tunicamycin compared to the sham group. 
Moreover, metformin reduced NADPH oxidase activity (Fig. 6a). The data were further 
confirmed by immunostaining (Fig. 6b).
It is important to mention that the sham mice group treated with metformin showed no 
differences in any parameters compared to the sham group alone (data not shown). Thus, to 
examine the overall data, we did not include the sham group treated with metformin in the 
results for easier interpretation.
Discussion
In the present study, we demonstrated that metformin inhibited Ang II-induced aberrant ER 
stress and vascular dysfunction through activation of AMPK. Such evidence came from our 
in vivo data in which hypertensive mice treated with metformin had reduced blood pressure 
and ameliorated vascular reactivity function. These results suggest that metformin is an 
important drug that plays a crucial role in reversing vascular complications during 
hypertension.
It is well established that hypertension is associated with vascular endothelial dysfunction 
[18]. We and others have successfully demonstrated that Ang II-induced hypertension 
reduces EDR, AMPK, and eNOS phosphorylation and enhances ER stress in MRA [19, 20]. 
Interestingly, treatment with metformin significantly reduced SBP. Our data agree with two 
studies with SHR rats treated with metformin that show a significant reduction in SBP [21, 
22]. Another meta-analysis study suggested that metformin could effectively lower SBP in 
nondiabetic patients [23]. Lowered blood pressure has also been reported in some clinical 
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studies, such as in nondiabetic, obese, and hypertensive women who received metformin [2]. 
The results demonstrated the feasibility and benefits of metformin beyond its glycemic 
control properties in nondiabetic mouse models.
Recently, we and others have documented a link between ER stress, hypertension, and 
cardiovascular diseases [19]. Additionally, emerging evidence using human and animal 
models has shown that elevated ER stress is an important contributor to the development of 
hypertension and cardiovascular diseases [24]. Thus, inhibition of ER stress offers a 
promising therapeutic tool for treating ER stress-mediated endothelial dysfunction. In the 
present study, we demonstrated that the activation of ER-induced endothelial dysfunction by 
a nonchemical inducer (Ang II) and by a chemical inducer (tunicamycin) could be 
suppressed after treatment with metformin. The relationship between ER stress and 
metformin is well documented in diabetes [25]. However, little is known about this 
relationship in nondiabetic hypertensive models, specifically in endothelial cells. A study by 
Duan et al. demonstrated that metformin treatment alleviated Ang II-induced ER stress in 
vascular smooth muscle cells (SMC) [20]. One limitation in our study was not 
differentiating between ECs and SMCs since our western blot was performed using the 
entire vessel. We assume that treatment with metformin has beneficial effects on ECs and 
not on SMCs since we did not see any differences among groups in response to contractile 
agents or NO donor agents, which act directly on SMCs. However, after treatment with 
metformin, our findings indicate an improvement in the damaged relaxation to ACh, which 
primarily depends on NO release from the ECs. Additional studies are needed to confirm 
this point.
AMPK has recently emerged as a key regulator of ER stress in different cell types. [26, 27] 
It has been reported that AMPK protects cardiomyocytes against hypoxia via attenuation of 
ER stress and suppresses palmitate-induced ER stress in endothelial cells and liver cells [28–
30]. In the vasculature, Duan et al. previously reported that metformin attenuates Ang II-
triggered hypertension in mice by activating AMPKα2, and metformin was also shown to 
inhibit Ang II-induced ER stress in vascular smooth muscle cells [20]. Our data agree with 
these studies since our results show that hypertensive mice treated with metformin restored 
the phosphorylated AMPK expression in vessels. Since dysfunction in AMPK signaling 
contributes to the development of hypertension and cardiovascular diseases [12], increasing 
AMPK activity during metformin treatment in hypertension may be of therapeutic value.
Ang-II-induced hypertension is a well-studied model for endothelial dysfunction [31]. 
Metformin treatment showed improvement in EDR associated with an increase in p-eNOS. 
The relationship between metformin and NO bioavailability has been documented in 
diabetic models, but little information is known about the relationship between NO and 
metformin in hypertensive models [32]. Although studies have shown that treating SHR rats 
with metformin increases NO in plasma and kidneys, NO bioavailability in the vasculature 
has not yet been evaluated [33]. Similarly, Pitocco et al. showed that treatment of 
streptozotocin (STZ)-SHR rats with metformin upregulated NO and thereby improved EDR 
[34]. Increased eNOS activation after metformin treatment is also in agreement with the 
results of a previous study by Davis et al., which showed that metformin improves 
endothelial vascular function by increasing AMPK-dependent, hsp90-mediated eNOS 
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activation in diabetes mellitus [32]. Furthermore, a study performed by Katakam et al. 
showed that metformin improves vascular function through a direct mechanism rather than 
by improving metabolic abnormalities [35]. Interestingly, while p-eNOS was restored, the 
EDR was partially recovered in our treated mice. A possible explanation is that superoxide 
anions, known to be induced during hypertension [36], neutralize endothelium-derived NO, 
which further results in diminished endothelium-dependent relaxation [37].
To evaluate this hypothesis, we measured the level of NADPH oxidase among groups. 
NADPH oxidases are the major sources of ROS in the arterial walls in pathological 
conditions, such as hypertension, diabetes, and aging. Therefore, NADPH oxidases are 
important contributors to oxidative stress and endothelial dysfunction [38]. Our data indicate 
that metformin reduced NADPH oxidase activity but not to the same level as the control. 
Therefore, the excessive O2 reduced the NO bioavailability, which could explain why a full 
relaxation did not occur in the hypertensive group treated with metformin. A study 
conducted by Anh et al. showed that endothelial cells treated with glucose in the presence of 
metformin was mediated by NADPH oxidase inhibition [39]. Additionally, studies have 
shown that metformin suppresses NADPH oxidase in podocytes [40]. Such data confirm the 
inhibitory role of metformin on NADPH oxidase in a nondiabetic model.
Treatment with metformin improved vascular function associated with a reduction in SBP. 
However, it was difficult to conclude whether the effect of metformin on AMPK, ER stress, 
NADPH oxidase, and eNOS was a direct or a consequence of the reduction in SBP. To 
confirm the direct effect of metformin on ER stress and to rule out that the beneficial effects 
of metformin on the vasculature were due to SBP reduction, we used a well-established 
model to induce ER stress in vivo without producing an increase in SBP. We treated mice 
with tunicamycin, which is a well-known ER stress inducer [18]. Our data indicate that mice 
treated with tunicamycin did not have increased SBP. SBP was in the same range as 
normotensive mice. These data agree with our previous study [12]. Our data indicate that 
metformin increases AMPK, inhibits tunicamycin-induced ER stress and NADPH oxidase, 
restores eNOS activity, and improves EDR. All these effects caused by metformin were 
independent of changes in SBP. Thus, metformin appears to improve vascular function 
independent of SBP. This study showed some of the beneficial pleiotropic effects of 
metformin independent of its effects on diabetes.
In summary, we demonstrated that metformin, independent of changes in SBP, improves 
vascular endothelium-dependent relaxation, increases eNOS activation, and suppresses ER 
stress and NADPH oxidase activity by activating AMPK. These results suggest that 
activation of metformin could be a useful therapeutic strategy for reversing vascular 
complications and cardiac damage from hypertension.
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Fig. 1. 
Metformin reduces systolic blood pressure and improves vascular function in hypertension. 
a The increased systolic blood pressure (SBP) in C57/Bl6 mice after Ang II infusion (400 
ng/kg/min) was significantly reduced with metformin treatment (300mg.kg−1 body weight 
per day). #p < 0.05 vs Sham; *p < 0.05 vs Sham + Ang II. b Body weight (BW) was similar 
among groups. c, d Contractile response to thromboxane analogue (U46619) and 
phenylephrine (PE) in mesenteric resistance arteries (MRA) was similar among groups. e 
Endothelial-dependent relaxation to acetylcholine (Ach) was damaged in the MRA of 
C57/Bl6 mice after Ang II infusion (400 ng/kg/min) and was significantly improved with 
metformin treatment (300 mg.kg−1 body weight per day). #p < 0.05 vs Sham; *p < 0.05 vs 
Sham + Ang II. f Endothelial-independent relaxation to sodium nitroprusside (SNP) was 
similar among groups. g Immunoblots for P-eNOS and T-eNOS and quantification of the 
ratio of P-eNOS/T-eNOS showed decreased eNOS activity in the MRA of C57/Bl6 mice 
after Ang II infusion (400 ng/kg/min), which was restored with metformin treatment (300 
mg.kg−1 body weight per day). *p < 0.05 vs Sham + Ang II
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Fig. 2. 
Metformin alleviates hypertension-induced ER stress by activating AMPK. a Immunoblots 
for ER stress markers (BIP, p-eIF2α/T-eIF2α, p-PERK, CHOP, and ATF6) and 
quantification showed increased ER stress markers in the MRA of C57/Bl6 mice after Ang 
II infusion (400 ng/kg/min) that was significantly reduced with metformin treatment 
(300mg.kg−1 body weight per day). *p < 0.05 vs Sham + Ang II. b Immunoblots for P-
AMPK and T-AMPK and quantification of the ratio of P-AMPK/T-AMPK showed 
decreased P-AMPK in the MRA of C57/Bl6 mice after Ang II infusion (400 ng/kg/min), 
which was further restored with metformin treatment (300 mg.kg−1 body weight per day). *p 
< 0.05 vs Sham + Ang II
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Fig. 3. 
Metformin inhibits oxidative stress. a NADPH oxidase activity and b immunofluorescence 
for 8-Oxo-2′-deoxyguanosine (8-OHDG) show an increase in oxidative stress in the MRA 
of C57/Bl6 mice after Ang II infusion (400 ng/kg/min), which was significantly reduced 
with metformin treatment (300 mg.kg−1 body weight per day).*p < 0.05 vs Sham + Ang II. 
#p < 0.05 vs Sham
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Fig. 4. 
Metformin improves vascular function independent of hypertension. a Systolic blood 
pressure (SBP) was similar among groups and in the range of normotensive values. b, c 
Contractile response to thromboxane analogue (U46619) and phenylephrine (PE) in 
mesenteric resistance arteries (MRA) was similar among groups. d Endothelial-dependent 
relaxation to acetylcholine (Ach) was damaged in the MRA of C57/Bl6 mice after 
intraperitoneal injection of tunicamycin (Tun, 1 mg/kg, two injections/week for 2 weeks) 
and was significantly improved with metformin treatment (300mg.kg−1 body weight per 
day). #p < 0.05 vs Sham; *p < 0.05 vs Sham + Tun. e Endothelial-independent relaxation to 
sodium nitroprusside (SNP) was similar among groups. f Immunoblots for P-eNOS and T-
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eNOS and quantification of the ratio of P-eNOS/T-eNOS showed decreased eNOS activity 
in the MRA of C57/Bl6 mice after intraperitoneal injection of tunicamycin (Tun, 1 mg/kg, 
two injections/week for 2 weeks), which was restored with metformin treatment (300mg.kg
−1
 body weight per day).*p < 0.05 vs Sham + Tun
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Fig. 5. 
Metformin alleviates tunicamycin-induced ER stress by activating AMPK. a Immunoblots 
for ER stress markers (BIP, p-PERK, and CHOP) and quantification showing increases in 
ER stress markers in the MRA of C57/Bl6 mice after intraperitoneal injection of 
tunicamycin (Tun, 1 mg/kg, two injections/week for 2 weeks) were significantly reduced 
with metformin treatment (300mg.kg−1 body weight per day). *p < 0.05 vs Sham + Tun. b 
Immunoblots for P-AMPK and T-AMPK and quantification of the ratio of P-AMPK/T-
AMPK showed decreased P-AMPK in the MRA of C57/Bl6 mice after intraperitoneal 
injection of tunicamycin (Tun, 1 mg/kg, two injections/week for 2 weeks), which was then 
restored with metformin treatment (300 mg.kg−1 body weight per day). *p < 0.05 vs Sham + 
Tun
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Fig. 6. 
Metformin inhibits oxidative stress. a NADPH oxidase activity and b immunofluorescence 
for 8-Oxo-2′-deoxyguanosine (8-OHDG) show an increase in oxidative stress in the MRA 
of C57/Bl6 mice after intraperitoneal injection of tunicamycin (Tun, 1 mg/kg, two 
injections/week for 2 weeks). Oxidative stress induced by tunicamycin was significantly 
reduced with metformin treatment (300mg.kg−1 body weight per day). *p < 0.05 vs Sham + 
Tun. #p < 0.05 vs Sham
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